Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
Medical therapy for clinical benign prostatic hyperplasia (BPH) has advanced significantly in the last 2 decades. Many new α1 antagonists and 5α reductase inhibitors (5ARi) are now commercially available. The practicing urologist must decide on the most appropriate medication for his patients, takin...
Main Authors: | Cheuk Fan Shum, Weida Lau, Chang Peng Colin Teo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-07-01
|
Series: | Asian Journal of Urology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221438821730053X |
Similar Items
-
Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
by: Hueih Ling Ong, et al.
Published: (2016-12-01) -
Radioimmunoassay for dihydrotestosterone and its use in studying benign prostatic hyperplasia patients undergoing treatment with 5α-reductase inhibitor.
Published: (1996) -
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
by: Eric H. Kim, et al.
Published: (2018-01-01) -
α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
by: Xiao-Feng Xu, et al.
Published: (2020-03-01) -
Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
by: Jae Seung Chung, et al.
Published: (2020-01-01)